Search - tctmd.com

Displaying 721 - 740 of 892

Sort: Relevancy | Date

News Featured Fellow

Fátima Rodriguez, MD, MPH

Yael L. Maxwell

March 10, 2016

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Conference News ISC 2016

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

Michael O'Riordan

February 23, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Daily News

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

L.A. McKeown

January 27, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

AHA Document Builds the Case for How to Improve Outcomes for Women With Acute MI

Caitlin E. Cox

January 25, 2016

News Daily News

比较分析表明无心衰患者使用 ACE 抑制剂和 ARB 类药物效果相当

Michael O'Riordan

January 19, 2016

News Daily News

Un Análisis Comparativo Sugiere que los Inhibidores de la ECA Equivalen a los ARB en Pacientes Sin Insuficiencia Cardíaca

Michael O'Riordan

January 19, 2016

News Daily News

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Michael O'Riordan

January 19, 2016

News Daily News

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

Michael O'Riordan

January 18, 2016

News Daily News

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Michael O'Riordan

December 20, 2015

News Daily News

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Michael O'Riordan

December 20, 2015

News Daily News

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Michael O'Riordan

December 20, 2015

News Daily News

For Interventional Trials, Optimal Medical Management May Entail as Much Training as New Techniques

Todd Neale

December 20, 2015

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Path to Top FDA Post Gets a Bit Rockier for Califf

Michael O'Riordan

December 09, 2015

News Conference News AHA 2015

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

Todd Neale

November 10, 2015

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

Advertisement

Fátima Rodriguez, MD, MPH

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

AHA Document Builds the Case for How to Improve Outcomes for Women With Acute MI

比较分析表明无心衰患者使用 ACE 抑制剂和 ARB 类药物效果相当

Un Análisis Comparativo Sugiere que los Inhibidores de la ECA Equivalen a los ARB en Pacientes Sin Insuficiencia Cardíaca

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

For Interventional Trials, Optimal Medical Management May Entail as Much Training as New Techniques

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Path to Top FDA Post Gets a Bit Rockier for Califf

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content